(19)
(11) EP 4 798 718 A1

(12)

(43) Date of publication:
02.09.2026 Bulletin 2026/36

(21) Application number: 24883511.8

(22) Date of filing: 28.10.2024
(51) International Patent Classification (IPC): 
C12N 15/113(2010.01)
A61K 31/7125(2006.01)
A61P 25/28(2006.01)
A61K 31/712(2006.01)
A61K 31/713(2006.01)
(52) Cooperative Patent Classification (CPC):
C12N 15/113; A61K 31/712; A61K 31/713; A61K 31/7125; A61P 25/28; C12N 2320/33; C12N 2310/11; C12N 2310/315; C12N 2310/322
 
C-Sets:
C12N 2310/322, C12N 2310/3533;
(86) International application number:
PCT/US2024/053253
(87) International publication number:
WO 2025/091028 (01.05.2025 Gazette 2025/18)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 27.10.2023 US 202363593746 P

(71) Applicants:
  • The Regents of The University of Michigan
    Ann Arbor, Michigan 48109 (US)
  • Rosalind Franklin University of Medicine and Science
    North Chicago, IL 60064 (US)
  • Ionis Pharmaceuticals, Inc.
    Carlsbad, CA 92010 (US)

(72) Inventors:
  • HASTINGS, Michelle L.
    Ann Arbor, Michigan 48109 (US)
  • CENTA, Jessica
    Chicago, Illinois 60064 (US)
  • STRATTON, Matthew
    Chicago, Illinois 60064 (US)
  • JAFAR-NEJAD, Paymaan
    Carlsbad, California 92010 (US)
  • HUNYARA, John
    Carlsbad, California 92010 (US)

(74) Representative: HGF 
HGF Limited 4th Floor, 1 City Square
Leeds LS1 2ES
Leeds LS1 2ES (GB)

   


(54) COMPOUNDS AND METHODS FOR MODULATING CLN3 EXPRESSION